ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Washington » Pulmonary Disease

Top Pulmonary Disease Prescribers in Washington

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
KENT SULLIVAN MD

Pulmonary Disease

13,692

$700K

379
307 are 65+

22%
patients receiving schedule two controlled substances

Avg: 2%

15%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 56%

$51
Average prescription price

Avg: $183

SCOTT SLAYMAKER MD

Pulmonary Disease

7,634

$401K

542
456 are 65+

6%
patients receiving schedule two controlled substances

Avg: 2%

13%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 56%

$52
Average prescription price

Avg: $183

RICHARD FELT MD

Pulmonary Disease

6,076

$301K

217
197 are 65+

7%
patients receiving schedule two controlled substances

Avg: 2%

18%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 56%

$50
Average prescription price

Avg: $183

JON HUSEBY M.D.

Pulmonary Disease

5,893

$418K

354
315 are 65+

5%
patients receiving schedule two controlled substances

Avg: 2%

9%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 56%

$71
Average prescription price

Avg: $183

THOMAS TAN MD

Pulmonary Disease

4,226

$439K

329
230 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

43%
prescriptions for brand name drugs

Avg: 56%

$104
Average prescription price

Avg: $183

BARRY MARMORSTEIN M.D.

Pulmonary Disease

3,791

$156K

255
211 are 65+

12%
patients receiving schedule two controlled substances

Avg: 2%

13%
patients receiving schedule three controlled substances

Avg: 1%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 56%

$41
Average prescription price

Avg: $183

JOHN FOWLER M.D.

Pulmonary Disease

2,909

$449K

418
342 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 56%

$154
Average prescription price

Avg: $183

TODD GREEN MD

Pulmonary Disease

2,866

$634K

348
257 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

66%
prescriptions for brand name drugs

Avg: 56%

$221
Average prescription price

Avg: $183

MICHAEL EULBERG

Pulmonary Disease

2,459

$322K

277
233 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

53%
prescriptions for brand name drugs

Avg: 56%

$131
Average prescription price

Avg: $183

WILLIAM PARK MD

Pulmonary Disease

2,446

$447K

273
220 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

53%
prescriptions for brand name drugs

Avg: 56%

$183
Average prescription price

Avg: $183

JEFFREY CARY MD

Pulmonary Disease

2,410

$521K

234
216 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

50%
prescriptions for brand name drugs

Avg: 56%

$216
Average prescription price

Avg: $183

JANET SELTZER M.D.

Pulmonary Disease

2,369

$321K

258
216 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 56%

$136
Average prescription price

Avg: $183

SAMUEL JOSEPH D.O.

Pulmonary Disease

2,336

$1.19M

238
164 are 65+

8%
patients receiving schedule two controlled substances

Avg: 2%

5%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 56%

$508
Average prescription price

Avg: $183

TODD FREUDENBERGER M.D.

Pulmonary Disease

2,304

$540K

255
233 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

4%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

67%
prescriptions for brand name drugs

Avg: 56%

$234
Average prescription price

Avg: $183

EMBRA ROPER M.D.

Pulmonary Disease

2,291

$160K

170
144 are 65+

8%
patients receiving schedule two controlled substances

Avg: 2%

11%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 56%

$70
Average prescription price

Avg: $183

GEORGE PAPPAS MD

Pulmonary Disease

2,103

$505K

252
220 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

68%
prescriptions for brand name drugs

Avg: 56%

$240
Average prescription price

Avg: $183

JOHN ROWLANDS MD

Pulmonary Disease

1,994

$537K

250
205 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

76%
prescriptions for brand name drugs

Avg: 56%

$269
Average prescription price

Avg: $183

KATHLEEN HORAN M.D.

Pulmonary Disease

1,975

$397K

251
204 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

53%
prescriptions for brand name drugs

Avg: 56%

$201
Average prescription price

Avg: $183

ISMAEL MATUS M.D.

Pulmonary Disease

1,904

$354K

214
167 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

74%
prescriptions for brand name drugs

Avg: 56%

$186
Average prescription price

Avg: $183

CAROLINA SEE MD

Pulmonary Disease

1,846

$442K

245
198 are 65+

5%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

68%
prescriptions for brand name drugs

Avg: 56%

$240
Average prescription price

Avg: $183

PHILLIP MENASHE M.D.

Pulmonary Disease

1,838

$472K

265
220 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

57%
prescriptions for brand name drugs

Avg: 56%

$257
Average prescription price

Avg: $183

GANESH RAGHU MD

Pulmonary Disease

1,747

$694K

142
91 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 56%

$397
Average prescription price

Avg: $183

STEVEN KIRTLAND MD

Pulmonary Disease

1,660

$245K

245
210 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

56%
prescriptions for brand name drugs

Avg: 56%

$148
Average prescription price

Avg: $183

JAMES COPELAND M.D.

Pulmonary Disease

1,643

$333K

201
184 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

50%
prescriptions for brand name drugs

Avg: 56%

$202
Average prescription price

Avg: $183

KITTREDGE BALDWIN D.O.

Pulmonary Disease

1,643

$304K

172
150 are 65+

0%
patients receiving schedule two controlled substances

Avg: 2%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 56%

$185
Average prescription price

Avg: $183

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank